Search results for N-terminal

CDKN2AIP N-terminal-like protein Antibody (HRP), Abbexa, abx108085

CDKN2AIP N-terminal-like protein Antibody (HRP) is a Rabbit Polyclonal antibody against CDKN2AIP N-terminal-like protein conjugated to HRP.

Procollagen III N-Terminal Propeptide (PIIINP) Antibody, Abbexa, abx131418

PIIINP Antibody is a Rabbit Polyclonal against PIIINP.

Anti-Thymosin alpha 1 antibody - N-terminal, Abcam, AB198880

Anti-TMEM106B antibody [EPR30569-128] - N-terminal, Abcam, AB325555

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Procollagen III N-Terminal Propeptide (PIIINP) Antibody, Abbexa, abx274841

This product is currently in development. The lead time for this product may be several months. Please contact us at [email protected] for an updated lead time before purchasing this product. Procollagen III N-Terminal Propeptide (PIIINP) Antibody is a Rabbit Monoclonal against Mouse PIIINP.

Protein N-terminal asparagine amidohydrolase (NTAN1) Antibody, Abbexa, abx340889

Protein N-terminal asparagine amidohydrolase (NTAN1) Antibody is a Rabbit Polyclonal antibody for the detection of Human NTAN1.

APC Anti-CD10 antibody [SP179] (N-terminal), Abcam, AB306504

This conjugated primary antibody is "made to order" and it is released using a quantitative quality control method that ensures binding affinity and labelling efficiency of the conjugate. Via leveraging the power of the Lightning-Link ® conjugation technology , Abcam will deliver highly consistent recombinant conjugates in <2 weeks, giving you access to an ever growing portfolio of antibody-label combinations. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

APC Anti-DNAJC7 antibody [EPR13349] (N-terminal), Abcam, AB306407

This conjugated primary antibody is "made to order" and it is released using a quantitative quality control method that ensures binding affinity and labelling efficiency of the conjugate. Via leveraging the power of the Lightning-Link ® conjugation technology , Abcam will deliver highly consistent recombinant conjugates in <2 weeks, giving you access to an ever growing portfolio of antibody-label combinations. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Anti-SARS spike glycoprotein antibody - N-terminal, Abcam, AB252691

Anti-Firefly Luciferase antibody [EPR17789] - N-terminal, Abcam, AB185923

What is this antibody validated in? Anti-Firefly Luciferase antibody [EPR17789] - N-terminal (ab185923) is a rabbit recombinant monoclonal antibody and is validated for use in Western Blot (WB), Flow Cytometry (Flow Cyt), Immunocytochemistry/immunofluorescence (ICC/IF) in Firefly samples. What is the molecular weight of Firefly Luciferase? Anti-Firefly Luciferase [EPR17789] - N-terminal (ab185923) specifically detects a band for Firefly Luciferase (UniProt: P08659) at a molecular weight of 61kDa. Trial sizes available! Test your antibody or perform pre-screening before committing to a larger quantity. Sold in 10µl. Discover our selection of trial-size antibodies. Other related products We have a range of other formats of antibody clone [EPR17789] also available for your convenience: ab185923, Alexa Fluor® 488 - ab237251 , Alexa Fluor® 647 - ab237252 , PE - ab237253 , Carrier free - ab238448 Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .